Page last updated: 2024-12-06

prednimustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Prednimustine: Ester of CHLORAMBUCIL and PREDNISOLONE used as a combination alkylating agent and synthetic steroid to treat various leukemias and other neoplasms. It causes gastrointestinal and bone marrow toxicity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID34457
CHEMBL ID2103751
CHEBI ID82524
SCHEMBL ID8246
MeSH IDM0017459

Synonyms (51)

Synonym
29069-24-7
sterecyt
nsc-134087
prednimustine
nsc-171345
(11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoate
hsdb 6882
prednimustine [usan:inn]
brn 2826967
pregna-1,4-diene-3,20-dione, 21-(4-(4-(bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)-11,17-dihydroxy-, (11beta)-
nsc 134087
prednisolone 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate)
chlorambucil ester of prednisolone
chlorambucil prednisolone ester
11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate)
leo-1031
prednimustinum [inn-latin]
ccris 6741
einecs 249-410-3
prednimustina [inn-spanish]
pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate)
pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-, 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate)
stereocyt
D05602
prednimustine (usan/inn)
[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate
C19512
prednimustinum
prednimustina
unii-9403sio2s8
9403sio2s8 ,
prednisolone chlorambucil ester
CHEMBL2103751
chebi:82524 ,
prednimustine [hsdb]
11.beta.,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate)
pregna-1,4-diene-3,20-dione, 21-(4-(4-(bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)-11,17-dihydroxy-, (11.beta.)-
prednimustine [who-dd]
prednimustine [inn]
prednimustine [mi]
prednimustine [usan]
prednimustine [iarc]
prednimustine [mart.]
SCHEMBL8246
HFVNWDWLWUCIHC-GUPDPFMOSA-N
DTXSID4021183
DB12832
Q7239694
CS-0007761
pregna-1,4-diene-3,20-dione, 21-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-11,17-dihydroxy-, (11beta)-
HY-13732

Research Excerpts

Overview

Prednimustine is an ester of chlorambucil and prednisolone.

ExcerptReferenceRelevance
"Prednimustine is an ester of chlorambucil and prednisolone. "( A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer.
Christiansen, IE; Dombernowsky, P; Løber, J; Mattsson, W; Mouridsen, HT; Rørth, M, 1983
)
2

Actions

ExcerptReferenceRelevance
"Prednimustine can produce durable responses in advanced ovarian cancer using a schedule that results in negligible toxicity."( Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
Cornbleet, MA; Fletcher, S; Kerr, GR; Leonard, RC; Livingstone, JR; Smart, GE; Smyth, JF; Webb, JN, 1989
)
1.3

Pharmacokinetics

The pharmacokinetic characteristics of prednisolone and of chlorambucil and its beta-oxidized metabolite, phenylacetic mustard (PAM) were studied in plasma after the oral administration of 200 mg prednimustine.

ExcerptReferenceRelevance
"The pharmacokinetic characteristics of prednisolone and of chlorambucil and its beta-oxidized metabolite, phenylacetic mustard (PAM) were studied in plasma after the oral administration of 200 mg prednimustine (Sterecyt) and a regimen consisting of 20 mg prednisolone plus 20 mg chlorambucil, respectively."( A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.
Bastholt, L; Gunnarsson, PO; Johansson, CJ; Johansson, SA; Mouridsen, H; Pfeiffer, P; Svensson, L, 1991
)
0.77
" This different pharmacokinetic behavior might offer an explanation for the superior therapeutic effects of prednimustine demonstrated by clinical studies."( Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.
Loos, U; Malek, M; Mühlenbruch, B; Musch, E; Oppitz, MM; Rüb, HP; von Unruh, GE, 1989
)
0.74

Compound-Compound Interactions

ExcerptReferenceRelevance
" In conclusion, it seems that prednimustine can be safely used in combination with methotrexate and 5-fluorouracil."( Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study.
Boesen, E; Mouridsen, HT, 1983
)
2

Bioavailability

The mean bioavailability was 14% for chlorambucil, 21% for phenylacetic acid mustard, and 22% for prednisolone. The bioavailability of orally administered prednimustine is much lower than that of chlorambuccil. It is suggested that prednisOLone plasma levels are as good a parameter of PrednimUSTine absorption and bioavailability as chlorambUCil levels.

ExcerptReferenceRelevance
" The mean bioavailability was 14% for chlorambucil, 21% for phenylacetic acid mustard, and 22% for prednisolone, when given as prednimustine, compared to the administration of free compounds in stoichiometrically equivalent doses."( Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration.
Loos, U; Malek, M; Musch, E; Riedel, E, 1991
)
0.74
" The bioavailability of chlorambucil was about five times lower when given as prednimustine as compared to administration of the free drug."( Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).
Ehrsson, H; Johansson, B; Nilsson, SO; Wallin, I, 1983
)
0.71
" the bioavailability of orally administered prednimustine is much lower than that of chlorambucil."( Studies on the pharmacokinetics of chlorambucil and prednimustine in man.
Calvert, AH; Harrap, KR; McElwain, TJ; Newell, DR, 1983
)
0.78
" It is suggested that prednisolone plasma levels are as good a parameter of Prednimustine absorption and bioavailability as chlorambucil levels, Prednimustine itself having never been detected in plasma."( Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone.
Hove, WV; Sayed, A; Vermeulen, A, 1981
)
0.74
" The bioavailability of oral idarubicin and of oral doxifluridine allows for their use in an oral 3 drug regimen."( Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer.
Alberto, P, 1993
)
0.53

Dosage Studied

ExcerptRelevanceReference
" This well-tolerated regimen is active in advanced high-risk elderly breast cancer patients, but dosage might be too low for younger patients and nonpretreated patients."( Preliminary analysis of combined treatment with prednimustine and 4'epidoxorubicin in advanced breast cancer.
Aapro, MS; Alberto, P; Forni, M; Krauer, F; Wählby, S, 1986
)
0.53
" 3 A preliminary comparison of chlorambucil levels following oral and intravenous administration, and after repeat oral dosage indicated that chlorambucil was well (greater than 70%) and consistently absorbed."( Studies on the pharmacokinetics of chlorambucil and prednimustine in man.
Calvert, AH; Harrap, KR; McElwain, TJ; Newell, DR, 1983
)
0.52
"Seventy-eight patients with advanced non-Hodgkin's lymphomas were randomized for treatment with prednimustine (Sterecyt) in two different schedules: either receiving continuous treatment at a dosage of 60 mg daily, or intermittent two-week courses with 200 mg daily for five days."( Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma.
Baldetorp, L; Carstensen, J; Håkansson, L; Hatschek, T; Möller, T; Nilsson, B; Termander, B, 1993
)
0.79
" One exception might be CBCC patients who were younger (median age 56 years) and who were usually in good general condition so that they might qualify for high dosage chemotherapy and stem cell support."( Outcome of patients with low-grade B cell non-Hodgkin lymphoma and initial bone marrow involvement: data of a single institution.
Heinz, R; Hopfinger, G; Tüchler, H, 1997
)
0.3
" No rational dosage forms make it possible to conduct clinical trials by parenteral administration."( [Pharmacological aspects in the development of liposomal medicinal preparations for the internal injection of hydrophobic cytostatics].
Baryshnikov, AIu; Oborotova, NA; Polozkova, ZS; Smirnova, ZS, 2002
)
0.31
" This observation suggests a strategy of individualized dosing adapted to hematotoxicity."( Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu, O; Diehl, V; Hasenclever, D; Loeffler, M, 2004
)
0.32
" Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated."( Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (139)

TimeframeStudies, This Drug (%)All Drugs %
pre-199077 (55.40)18.7374
1990's49 (35.25)18.2507
2000's9 (6.47)29.6817
2010's4 (2.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.17 (24.57)
Research Supply Index5.26 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials46 (31.72%)5.53%
Reviews12 (8.28%)6.00%
Case Studies6 (4.14%)4.05%
Observational1 (0.69%)0.25%
Other80 (55.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
PROSPECTIVE NON-RANDOMIZED STUDY WITH CHEMOTHERAPY FOR RELAPSED OR REFRACTORY HIV-RELATED NON-HODGKIN'S LYMPHOMA: VMP REGIMEN FOR RELAPSED PATIENTS, CDE REGIMEN FOR REFRACTORY PATIENTS [NCT00002905]Phase 220 participants (Anticipated)Interventional1995-06-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]